PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20160907-7 2009 Finally, we compared the collisional activation data for the MCP-1 dimer with an MCP-1 dimer non-covalently bound to a single molecule of the semi-synthetic glycosaminoglycan (GAG) analog Arixtra ; the latter a therapeutic anti-thrombin III-activating pentasaccharide. Glycosaminoglycans 157-174 C-C motif chemokine ligand 2 Homo sapiens 81-86 20160907-7 2009 Finally, we compared the collisional activation data for the MCP-1 dimer with an MCP-1 dimer non-covalently bound to a single molecule of the semi-synthetic glycosaminoglycan (GAG) analog Arixtra ; the latter a therapeutic anti-thrombin III-activating pentasaccharide. Glycosaminoglycans 176-179 C-C motif chemokine ligand 2 Homo sapiens 81-86 16385517-7 2006 RESULTS: The glycosaminoglycan chondroitin sulfate, but not fibronectin or collagens, bound and released MCP-1 in a time-dependent manner. Glycosaminoglycans 13-30 C-C motif chemokine ligand 2 Homo sapiens 105-110 10504268-3 1999 Chemokines bind to glycosaminoglycans on human umbilical vein endothelial cells (HUVECs) with affinities in the micromolar range: RANTES > MCP-1 > IL-8 > MIP-1alpha. Glycosaminoglycans 19-37 C-C motif chemokine ligand 2 Homo sapiens 142-147 12805068-3 2003 Infection of monocyte-derived macrophages with laboratory-adapted HIV-1 or primary viral isolates in the continuous presence of anti-CCL2 antibody resulted in significantly lower p24 Gag antigen release with respect to control cultures. Glycosaminoglycans 183-186 C-C motif chemokine ligand 2 Homo sapiens 133-137 12805068-4 2003 Interestingly, CCL2 neutralization did not affect the early steps of the HIV life cycle but resulted in the intracellular accumulation of p24 Gag antigen. Glycosaminoglycans 142-145 C-C motif chemokine ligand 2 Homo sapiens 15-19 9354625-9 1997 The endothelial cell binding sites for IL-8, RANTES, and MCP-1 were deduced to be glycosaminoglycans since competition assays showed the biphasic curves and micromolar IC50 values seen in studies with immobilized heparin, and mRNA for known chemokine receptors was not detected. Glycosaminoglycans 82-100 C-C motif chemokine ligand 2 Homo sapiens 57-62 9792674-9 1998 Therefore, we conclude that the Lys-58 and His-66 residues in the C-terminal alpha-helix of MCP-1 are essential for glycosaminoglycan binding and probably for the binding to the endothelial surface proteoglycans. Glycosaminoglycans 116-133 C-C motif chemokine ligand 2 Homo sapiens 92-97 9354625-12 1997 Removal of glycosaminoglycans from CHO cells expressing chemokine receptors CXCR1, CCR1, or CCR2 resulted in 40-70% decreases in the binding of RANTES, MCP-1, IL-8, and MIP-1alpha. Glycosaminoglycans 11-29 C-C motif chemokine ligand 2 Homo sapiens 152-157 34112803-4 2021 Here, we show that microenvironmental cytokines, particularly CCL2, decorate cancer exosomes via binding to surface glycosaminoglycan side chains of proteoglycans, causing exosome accumulation in specific cell subsets and organs. Glycosaminoglycans 116-133 C-C motif chemokine ligand 2 Homo sapiens 62-66 25608886-5 2015 RESULTS: CCL2 neutralization potently reduced the number of p24 Gag+ cells during the course of either productive or single cycle infection with HIV-1. Glycosaminoglycans 64-67 C-C motif chemokine ligand 2 Homo sapiens 9-13 32923824-10 2020 As the residues R18, R24, and K49 of hCCL2 are crucial determinants of monocyte trafficking through receptor/glycosaminoglycans (GAG) binding in CCL2 human/murine orthologs, we propose that baicalin engaging these residues in complex formation will result in attenuation of CCL2 binding to the receptor/GAGs, thus inhibiting the chemokine-regulated leukocyte trafficking. Glycosaminoglycans 129-132 C-C motif chemokine ligand 2 Homo sapiens 38-42 33781652-0 2021 Glycosaminoglycans located on neutrophils and monocytes impact on CXCL8- and CCL2-induced cell migration. Glycosaminoglycans 0-18 C-C motif chemokine ligand 2 Homo sapiens 77-81 32923824-10 2020 As the residues R18, R24, and K49 of hCCL2 are crucial determinants of monocyte trafficking through receptor/glycosaminoglycans (GAG) binding in CCL2 human/murine orthologs, we propose that baicalin engaging these residues in complex formation will result in attenuation of CCL2 binding to the receptor/GAGs, thus inhibiting the chemokine-regulated leukocyte trafficking. Glycosaminoglycans 109-127 C-C motif chemokine ligand 2 Homo sapiens 37-42 32923824-10 2020 As the residues R18, R24, and K49 of hCCL2 are crucial determinants of monocyte trafficking through receptor/glycosaminoglycans (GAG) binding in CCL2 human/murine orthologs, we propose that baicalin engaging these residues in complex formation will result in attenuation of CCL2 binding to the receptor/GAGs, thus inhibiting the chemokine-regulated leukocyte trafficking. Glycosaminoglycans 109-127 C-C motif chemokine ligand 2 Homo sapiens 38-42 32923824-10 2020 As the residues R18, R24, and K49 of hCCL2 are crucial determinants of monocyte trafficking through receptor/glycosaminoglycans (GAG) binding in CCL2 human/murine orthologs, we propose that baicalin engaging these residues in complex formation will result in attenuation of CCL2 binding to the receptor/GAGs, thus inhibiting the chemokine-regulated leukocyte trafficking. Glycosaminoglycans 129-132 C-C motif chemokine ligand 2 Homo sapiens 37-42 20097750-4 2010 We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked out CCR2 activity, which were designed to interrupt the MCP-1/CCL2-related signaling cascade. Glycosaminoglycans 68-71 C-C motif chemokine ligand 2 Homo sapiens 34-39 23983782-6 2013 Results showed that the hyperglycemia-induced GAG alterations in the cell surface perlecan as well as in the ECM indeed upregulated the expressions of IL-6, IL-8, and MCP-1 and the activities of MMP-2 and MMP-9 and downregulated the expressions of TIMP-2. Glycosaminoglycans 46-49 C-C motif chemokine ligand 2 Homo sapiens 167-172 20097750-4 2010 We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked out CCR2 activity, which were designed to interrupt the MCP-1/CCL2-related signaling cascade. Glycosaminoglycans 68-71 C-C motif chemokine ligand 2 Homo sapiens 40-44 20097750-4 2010 We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked out CCR2 activity, which were designed to interrupt the MCP-1/CCL2-related signaling cascade. Glycosaminoglycans 68-71 C-C motif chemokine ligand 2 Homo sapiens 157-162 20097750-4 2010 We have therefore generated novel MCP-1/CCL2 mutants with increased GAG binding affinity and knocked out CCR2 activity, which were designed to interrupt the MCP-1/CCL2-related signaling cascade. Glycosaminoglycans 68-71 C-C motif chemokine ligand 2 Homo sapiens 163-167